Cover Image

Outcomes of patients with EGFR-mutant advanced NSCLC in a developing country in Southeast Asia

Background: Although first-and second-generation EGFR TKIs are considered first-line treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly, EGFR T790M mutation. The third-generation EGFR-TKI has demonstrated efficacy in patients with progressive disease harboring the T79...

Full description

Saved in:

Bibliographic Details
Main Authors:	How, Soon Hin, Liam, Chong Kin, Abidin, Muhammad Adil Zainal, Hasbullah, Harissa H., Tho, Lye Mun, Ho, Gwo Fuang, Nor, Ibtisam Muhamad, Pang, Yong Kek, Ho, Kean Fatt, Thiagarajan, Muthukkumaran, Ariffin, Roziana, Samsudin, Azlina, Omar, Azza, Tan, Sin Nee, Ong, Choo Khoon, Soon, Sing Yang, Poh, Mau Ern
Format:	Article
Published:	Dove Medical Press LTD 2022
Subjects:	R Medicine
Online Access:	http://eprints.um.edu.my/42092/
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Outcomes of patients with EGFR-mutant advanced NSCLC in a developing country in Southeast Asia
by: How, Soon Hin, et al.
Published: (2022)

Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
by: Mau, Ern Poh, et al.
Published: (2024)

Intermittent EGFR-TKI therapy is associated with durable response in advanced EGFR-mutant NSCLC: a case report
by: Tan, Sin Nee, et al.
Published: (2023)

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
by: Ho, Gwo Fuang, et al.
Published: (2019)

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
by: Chai, Chee Shee, et al.
Published: (2019)

Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country
by: How, Soon Hin, et al.
Published: (2022)

Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country
by: Poh, Mau Ern, et al.
Published: (2023)

Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma
by: Poh, Mau Ern, et al.
Published: (2018)

Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma
by: Chai, Chee Shee, et al.
Published: (2018)

Real-world treatment and outcomes of ALK-positive metastatic non–small cell lung cancer in a southeast Asian country
by: Poh, Mau Ern, et al.
Published: (2023)

Real-world multicentre experience of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer
by: Liam, Chong Kin, et al.
Published: (2019)

Afatinib as first-line treatment in Asian patients with EGFR mutation-positive NSCLC: A narrative review of real-world evidence
by: Lu, Shun, et al.
Published: (2021)

Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
by: Chai, Chee Shee, et al.
Published: (2019)

Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
by: Chai, Chee Shee, et al.
Published: (2019)

Robust radiogenomics approach to the identification of EGFR mutations among patients with NSCLC from three different countries using topologically invariant Betti numbers
by: Ninomiya, Kenta, et al.
Published: (2021)

Robust radiogenomics approach to the identification of EGFR mutations among patients with NSCLC from three different countries using topologically invariant Betti numbers
by: Ninomiya, Kenta, et al.
Published: (2021)

P3. 13-15 First-Line Afatinib Dose Initiation and Adjustment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
by: Chai, Chee Shee, et al.
Published: (2018)

P3. 15-21 Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer.
by: Chai, Chee Shee, et al.
Published: (2018)

Molecular docking analysis on the designed benzimidazole derivatives as EGFR inhibitors: comparison between EGFR wild-type (EGFRWT) and T790M mutant
by: Nurul Awani Syazzira Jalil,, et al.
Published: (2023)

Molecular Docking analysis on the designed Benzimidazole derivatives as EGFR inhibitors: comparison between EGFR Wild-Type (EGFRWT) and T790M Mutant
by: Jalil, Nurul Awani Syazzira, et al.
Published: (2023)

Acquired T790M Mutation in Patients Failing Treatment with First or Second-Generation EGFR-Tyrosine Kinase Inhibitors
by: Chai, Chee Shee, et al.
Published: (2019)

Asian thoracic oncology research group expert consensus statement on optimal management of stage III NSCLC
by: Tan, Wan Ling, et al.
Published: (2020)

Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance
by: Zhang, Chuanfen, et al.
Published: (2022)

Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
by: Chai, Chee Shee, et al.
Published: (2020)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: Von Cheong, E., et al.
Published: (2021)

A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
by: Von, Cheong E., et al.
Published: (2021)

Immunoexpression of BRAF, EGFR and CD10 in ameloblastoma
by: Tan, Chuey Chuan, et al.
Published: (2022)

In-silico Studies of the Antiproliferative Activity of New Anilinoquinazoline Derivatives Against NSCLC Cells
by: Abdulwahab, Muhammad Kumayl, et al.
Published: (2021)

In-silico studies of the antiproliferative activity of new anilinoquinazoline derivatives against nsclc cells
by: Abdulwahab, Muhammad Kumayl, et al.
Published: (2021)

Characteristics of epidermal growth factor receptor (EGFR)-Mutated Non Small Cell Lung Carcinoma (NSCLC)-patients who developed resistance to first or second generation Egfrtyrosine Kinase Inhibitor (TKI) Therapy through T790M mutation / Vijayan Munusamy
by: Vijayan, Munusamy
Published: (2017)

Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer
by: Poh, Mau Ern, et al.
Published: (2024)

Asian Thoracic Oncology Research Group (ATORG) expert consensus statement on MET alterations in NSCLC: Diagnostic and therapeutic considerations
by: Ahn, Myung-Ju, et al.
Published: (2022)

$A promising response of refractory uterine leiomyosarcoma to pembrolizumab and temozolomide combination therapy$

A promising response of refractory uterine leiomyosarcoma to pembrolizumab and temozolomide combination therapy
by: Lin, Rebecca, et al.
Published: (2024)

Differential proteome and functional analysis of NSCLC cell lines in response to Tualang honey treatment
by: Amran, Nazirah, et al.
Published: (2022)

Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC)
by: Ashique, Sumel, et al.
Published: (2023)

Epidermal growth factor receptor (EGFR) mutations are the main oncogenic driver mutation in adenocarcinoma in never-smokers - findings from the emlan study
by: Liam, Chong Kin, et al.
Published: (2012)

Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.]
by: Hasbullah, Harissa H, et al.
Published: (2018)

Strep-tag ii mutant maltose-binding protein for reagentless fluorescence sensing
by: Hasmoni, Siti Halimah, et al.
Published: (2016)

The 4717C > G polymorphism in periplakin modulates sensitivity to EGFR inhibitors
by: Lee, Hui Mei, et al.
Published: (2019)

Lung cancer in Malaysia
by: Rajadurai, Pathmanathan, et al.
Published: (2020)